Please use this identifier to cite or link to this item:
|Title:||Alterations on peripheral blood B-cell subpopulations in very early arthritis patients|
|Authors:||Moura, Rita A.|
Pereira, Patrícia A.
Mourão, Ana F.
Rodrigues, Ana M.
Queiroz, Mário V.
Souto-Carneiro, Maria M.
Fonseca, João E.
|Publisher:||Oxford University Press|
|Abstract:||Objective. To characterize circulating B-cell subpopulations of arthritis patients with <6 weeks of disease duration. Methods. Peripheral blood samples were collected from very early untreated polyarthritis patients, with <6 weeks of disease duration, for flow cytometric evaluation of B-cell subpopulations. Samples from patients who were later diagnosed as RA [very early RA (VERA)] were also collected 4–6 weeks after starting a low dose of prednisone (5–10 mg) and 4 months after reaching the minimum effective dose of MTX. A matched healthy group was used as a control. Results. VERA patients have a lower percentage of total peripheral blood memory B cells (CD19+CD27+) and a significant decrease in the frequency of circulating pre-switch memory B cells (CD19+IgD+CD27+) as compared with controls. Therapy with corticosteroids or MTX was unable to restore the normal frequencies of these B-cell subpopulations. A significant decrease in peripheral pre-switch memory B cells is equally observed in other early arthritis patients. Furthermore, no significant differences are found in the frequencies of CD4+ and CD8+ T cells in all patient groups. Conclusions. In very early polyarthritis patients, there is a reduction in circulating pre-switch memory B cells. The reasons that may account for this effect are still unknown. Short-term corticosteroids and MTX do not seem to have a direct effect on circulating B-cell subpopulations in VERA patients.|
|Description:||©The Author 2010. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.|
|Appears in Collections:||IMM - Artigos em Revistas Internacionais|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.